Publikationen

Links

Research gate, Google scholar, Pub Med

Originalarbeiten

  1. Leeb B, Dunky A, Berger E et al.: Retrospektive Beurteilung über zehn Jahre Anwendung von Levamisole als Basistherapeutikum bei chronischer Polyarthritis. TW Österreich 12; 1112 – 1117; 1988
  2. Leeb B, Dunky A, Ogris E. et al.: Methotrexate serum-level determinations during low-dose Methotrexate therapy of psoriatic and rheumatoid Arthritis. Int J Clin Pharm Res IX(3); 209 – 215; 1989
  3. Leeb B, Dunky A, Ogris E. et al.: Hämatozelluläres Methotrexate bei Langzeittherapie entzündlich rheumatischer Erkrankungen. Acta Med Austr 16/5; 140 – 145; 1989
  4. Leeb B, Dell HD: Injektionstherapie mit Etofenamat. Z Allg Med 67; 1299 – 1302; 1991
  5. Leeb B: Topisches Felbinac in der Therapie von Sportverletzungen. Fortschr Med. 1994; 112 (6): 77 – 80;
  6. Leeb BF, Witzmann G, Ogris E, Studnicka-Benke A, Andel I, Schweitzer H, Smolen JS: Folic acid and cyanocobalamin levels in serum and erythrocytes during low-dose methotrexate therapy of rheumatoid arthritis and psoriatic arthritis patients. Clin Exp Rheumatol 1995; 13(4): 459 – 463
  7. Leeb BF, Petera P, Neumann K: Anwendungsbeobachtung von Chondroitinsulfat bei aktivierten Arthrosen. Wr Med Wschr 1996; 146 (24): 609 – 614
  8. Leeb BF, Schweitzer H, Montag K, Smolen JS: A meta-analysis of chondroitinsulfate in the treatment of osteoarthritis. J Rheumatol 2000; 27: 205 – 211
  9. Leeb BF, Sautner J, Andel I, Rintelen B: SACRAH – A Score for Assessment and Quantification of Chronic Rheumatic Affections of the Hands, Rheumatology (Oxford). 2003 Oct;42(10):1173-8. Epub 2003 May 30.
  10. Leeb BF, Bird HA, Nesher G, Andel I, Hueber W, Logar D, Montecucco C, Rovensky J, Sautner J, Sonnenblick M: EULAR response criteria for Polymyalgia rheumatica. Results of an initiative of the European collaborating Polymyalgia Rheumatica group (Subcommittee of ESCISIT [EULAR Standing Committee on Clinical Trials Including Therapeutical Trials]) Ann Rheum Dis 2003; 62: 1189-1194;
  11. Leeb BF, Bird HA: A disease activity score for Polymyalgia Rheumatica (PMR-AS) Ann Rheum Dis 2004, 63: 1279-1283;
  12. Leeb BF, Bucsi B, Keszthelyi B, Böhmova J, Valesova M, Hawel R, Mayrhofer F, Singer F,Aglas F, Bröll H: Retardiertes Acemetacin und Celecoxib im Vergleich bei der Behandlung der Gonarthrose. Der Orthopäde 2004, 33 (9): 1032 – 1041; published online first 20/05/2004
  13. Leeb BF, Andel I, Sautner J, Nothnagl Th, Rintelen B: The DAS28 in Rheumatoid Arthritis and Fibromyalgia patients; Rheumatology 2004;43:1504 – 1507 , Advance Access published online on July 13, 2004
  14. Leeb BF, Andel I, Sautner J, Bogdan M, Maktari A, Nothnagl T, Rintelen B: Disease activity measurement of Rheumatoid Arthritis. Comparison of the SDAI and the DAS28 in daily routine. Arthritis Rheum (Arthritis Care Res), 2005; 53 (1): 56 – 61
  15. Leeb BF, Andel I, Leder S, Leeb BA, Rintelen B: The patient’s perspective and disease activity indexes. Rheumatology (Oxford). 2005 Mar;44(3):360-365; Advance Access published online on November 30, 2004
  16. Leeb BF, Sautner J, Andel I, Rintelen B: Intravenous Application of Omega-3-Fatty Acids in Patients with Active Rheumatoid Arthritis. The ORA-1 Trial. An open Pilot-Study. Lipids, 41: 29 – 34; 2006
  17. Leeb BF, Sautner J, Leeb BA, Fassl Ch, Rintelen B: Lack of Agreement between the Patient’s and Physician’s Perception of Rheumatoid Arthritis’ Disease Activity changes. Scand J Rheumatol 35 (6) 2006, 441 – 446
  18. Leeb BF, Andel I, Sautner J, Fassl Ch, Nothnagl Th, Rintelen B: The DAS28 in Rheumatoid Arthritis and Psoriatic Arthritis Patients. Arthritis Rheum (AC&R) 57 (2), 256 – 260; 2007
  19. Leeb BF, Rintelen B, Sautner J, Fassl Ch, Bird HA: The Polymyalgia Rheumatica Activity Score (PMR-AS) in daily use. – Proposal for a Definition of Remission. Arthr Rheum (AC&R), 2007 Jun 15;57(5):810-5. 2006,
  20. Leeb BF, Latta HJ, Haindl P, Maktari A, Rintelen B. Hyaluronan (Erectus®) in der Behandlung der Osteoarthritis des Kniegelenkes – Ergebnisse einer offenen Anwendungsbeobachtung. J Miner Stoffwechs, 2007 14(1); 32 – 35
  21. Leeb BF, Haindl PM, Maktari A, Nothnagl T, Rintelen B. Disease activity score-28 values differ considerably depending on patient’s pain perception and sex. J Rheumatol. 2007 Dec;34(12):2382-7. Epub 2007 Nov 1.
  22. Leeb BF, Haindl PM, Maktari A, Nothnagl T, Rintelen B. Patient Centered Rheumatoid Arthritis Activity Assessment by a Modified RADAI. J Rheumatol 2008, Jul;35(7):1294-9. Epub 2008 May 15.
  23. Leeb BF, Sautner J, Mai HTH, Haindl PM, Deutsch C, Rintelen B. A Comparison of Patient Questionnaires and Composite Indexes in Routine Care of Rheumatoid Arthritis Patients. Joint Bone Spine, 2009 Dec;76(6):658-64. doi: https://doi.org/10.1016/j.jbspin.2009.04.001. Epub 2009,
  24. Leeb BF, Böttcher E, Brezinschek HP, Czerwenka C, Herold M, Hitzelhammer H, Mayrhofer F, Puchner R, Rainer F, Rintelen B, Schirmer M, Stuby U, Bröll H. The use of Tumor necrosis factor alpha-blockers in daily routine. An Austrian consensus project. Clin Rheumatol. 2010 Feb;29(2):167-74. doi: https://doi.org/10.1007/s10067-009-1304-y. Epub 2009 Nov 11.2009,
  25. Leeb BF, Haindl PM, Brezinschek HP, Mai HT, Deutsch C, Rintelen B. Patient-centered psoriatic arthritis (PsA) activity assessment by Stockerau Activity Score for Psoriatic Arthritis (SASPA). BMC Musculoskelet Disord. 2015 Apr 1;16:73. doi: https://doi.org/10.1186/s12891-015-0512-7.
  26. Leeb BF, Singer F, Stummer O, und Herold M, in Namen der BioReg Investigatoren. Biologika-Therapien in Österreich. Daten aus dem Österreichischen Biologika-Register BioReg; Aktuelle Rheumatol. 2018; 43(05): 395-405 DOI: https://doi.org/10.1055/a-0584-5830 2018,
  27. Leeb BF, Lunzer R, Fasching P, Herold M, Zamani O, Riedlmaier U, Schimetta W, Graninger WB. OPTIMISE: An Austrian multicentre study on the effectiveness and safety of tocilizumab in combination with methotrexate versus tocilizumab for mild/moderate rheumatoid arthritis and an inadequate response to methotrexate. Journal Rheum Dis Treat, 2019, 5:074. https://doi.org/10.23937/2469-5726/1510074
  28. Leeb BF, Spellitz P, Eichbauer-Sturm G, Herold M, Stetter M, Puchner R, Singer FSt. Fritsch RDE. Januskinase Inhibitors to Treat Rheumatoid Arthritis: Real World Data Match Clinical Trial Results. An Evaluation by BioReg, the Austrian Registry for Biologicals, Biosimilars, and Targeted Synthetic DMARDS in the Treatment of Inflammatory Rheumatic Diseases. July 2021; Rheumatology Current Research 11(5):1-7;DOI: 10.35248/2161-1149.21.11.288
  29. Gaismayer K, Neumüller J, Dunky A, Leeb B, Eberl R.: Phagozytose von polymorphkernigen Granulozyten und Monozyten. TW Österreich 11, 1162 – 1165; 1987
  30. Dunky A, Menzel J, Leeb B et al.: Prokollagen-III-Peptid und Methotrexat-Spiegelbestimmungen unter „low-dose“ Methotrexattherapie bei entzündlichen Gelenkerkrankungen. TW Österreich 12; 1102 – 1111; 1988
  31. Siegmeth W, Leeb B, Dunky A.: Wirksamkeit eines 3%igen Felbinac-Gels. Fortschr Rheumatol. 1; 6 – 9; 1991
  32. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen J, Leeb B, Breedveld FC, Macfarlane JD, Bijl H et al.: Randomised double blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) in rheumatoid arthritis. Lancet 1994; 344: 1105 – 1110;
  33. Partsch G, Petera P, Leeb B, Meretey K; Koo E, Dunky A, Bröll H, Zamani O, Fertschak W, Matucci-Cerinic et al.: High free and latent collagenase activity in psoriatic arthritis synovial fluids. Br J Rheumatol 1994; 33(8): 702 – 706;
  34. Stiskal M, Neuhold A, Szolar DH, Saeed M, Czerny C, Leeb B, Smolen J, Czembirek H: Rheumatoid arthritis of the craniocervical region by MR imaging: detection and characterization. Am J Roentgen 1995; 165 (3): 585 – 592
  35. Partsch G, Leeb B, Stancikova M, Raffayova H, Eberl G, Hitzelhammer H, Smolen JS: Low serum hyaluronan in psoriatic arthritis patients in comparison to rheumatoid arthritis patients. Clin Exp Rheumatol 1996; 14: 381 – 386
  36. Partsch G, Steiner G, Leeb BF, Dunky A, Bröll H, Smolen JS: Highly increased levels of tumor necrosis factor alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997; 24: 518 – 523
  37. Partsch G, Wagner E, Leeb BF, Dunky A, Steiner G, Smolen JS: Upregulation of cytokine receptors sTNF-R55, sTNF-R75, and sIL-2R in psoriatic arthritis synovial fluid. J Rheumatol 1998; 25: 105 – 110
  38. Partsch G, Wagner E, Leeb BF, Bröll H, Dunky A, Smolen JS: T cell derived cytokines in psoriatic arthritis synovial fluids. Ann Rheum Dis. 1998; 57 (11): 691 – 693
  39. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davies D, MacFarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M: Therapeutic efficacy of multiple intravenous infusions of anti-TNFα antibody combined with low dose weekly methotrexate in rheumatoid arthritis. Arthr Rheum 1998; 41: 1552 – 1563
  40. Machold KP, Eberl G, Leeb BF, Nell V, Windisch B, Smolen JS: Early arthritis: Rationale and current approach. J Rheumatol 1998; 25 Suppl. 53: 13 – 19
  41. Pendleton A, Arden N, Dougados M, Doherty M, Bannwarth B, Bijlsma JWJ, Cluzeau F, Cooper C, Dieppe PA, Gunther KP, Häuselmann HJ, Herrero-Beaumont G, Kaklamanis PK, Leeb B, Lequesne M, Lohmander S, Mazieres B, Mola EM, Pavelka K, Serni U, Swoboda B, Verbruggen AA, Weseloh G, Zimmermann-Gorska I: EULAR recommendations for the management of knee osteoarthritis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutical Trials (ESCISIT). Ann Rheum Dis 2000; 59: 936 – 944
  42. Lemmel EM, Leeb BF, De Bast J, Aslanidis S: Patient and Physician Satisfaction with Aceclofenac: Results of the European Observational Cohort Study (Experience with Aceclofenac for Inflammatory Pain in Daily Practice). Curr Med Res Opin 18(3); 146 – 153, 2002
  43. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma J, Dieppe P, Gunther K, Hauselmann H, Herrero-Beaumont G, Kaklamanis P, Lohmander S, Leeb B, Lesquesne M, Mazieres B, Mola E, Pavelka K, Pendleton A, Punzi L, Serni U, Swoboda B, Verbruggen G, Zimmermann-Gorska I, Dougados M;: EULAR Recommendations 2003: An evidence based medicine approach to the management of knee osteoarthritis. Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145-1155
  44. Stranzl T, Wolf J, Leeb BF, Smolen JS, Pirker R, and Filipits M: Expression of Folylpolyglutamyl Synthetase predicts poor response to Methotrexate therapy in patients with rheumatoid arthritis, Clin Exp Rheumatol, 2003; 21: 27 – 32
  45. Sautner J, Andel I, Rintelen B, Leeb BF: M-SACRAH. A modified, shortened version of SACRAH (Score for the Assessment and Quantification of Chronic Rheumatoid Affections of the Hands); Rheumatology (Oxford). 2004 Nov;43(11):1409-13. Epub 2004 Aug 10.
  46. Wolf J, Stranzl Th, Filipits M, Pohl G, Pirker R, Leeb BF, Smolen JS: Expression of Resistance Markers to Methotrexate (MTX) predicts clinical improvement in Patients with Rheumatoid Arthritis. Ann Rheum Dis. 2005 Apr;64(4):564-8. Epub 2004 Sep 2.
  47. Bird HA, Leeb BF, Montecucco CM, Misiuniene N, Nesher G, Pai S, Pease C, Rovensky J, and Rozman B: A Comparison of the sensitivity of diagnostic criteria for polymyalgia rheumatica. Ann Rheum Dis. 2005 Apr;64(4):626-9
  48. Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Günther KP, Häuselmann HJ, Herrero-Beaumont G, Jordan K, Kakamanlis P, Leeb BF, Lequesne M, Lohmander S, Mazieres B, Martin-Mola E, Pendleton A, Pavelka K, Punzi L, Swoboda B, Varatojo R, Verbruggen G, Zimmermann-Gorska I, Dougaods M: EULAR evidence based recommendations for the management of hip osteoarthritis – report of a task force of the EULAR standing committee for international clinical studies including therapeutics ESCISIT). Ann Rheum Dis. 2005 May;64(5):669-81. Epub 2004 Oct 7.
  49. Rintelen B, Sautner J, Andel I, Leeb BF: Leflunomide / Chloroquin combination therapy in Rheumatoid Arthritis. A pilot study. Clin Rheumatol 2006, 25; 557 – 559; epub ahead of print Jan 4th, 2006
  50. Zhang W, M. Doherty, E. Pascual, T. Bardin, V. Barskova, P. Conaghan, J. Gerster, J. Jacobs, B. Leeb, F. Lioté, G. McCarthy, P. Netter, G. Nuki, F. Perez-Ruiz, A. Pignone, J. Pimentão, L. Punzi, E. Roddy, T. Uhlig, I. Zimmermann-Gòrska. eular Evidence Based Recommendations for Gout – Part I Diagnosis. Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006 May 17; [Epub ahead of print]
  51. Zhang W, M. Doherty, E. Pascual, T. Bardin, V. Barskova, P. Conaghan, J. Gerster, J. Jacobs, B. Leeb, F. Lioté, G. McCarthy, P. Netter, G. Nuki, F. Perez-Ruiz, A. Pignone, J. Pimentão, L. Punzi, E. Roddy, T. Uhlig, I. Zimmermann-Gòrska. eular Evidence Based Recommendations for gout- Part II Management. Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006, May 30; [Epub ahead of print]
  52. Rintelen B, Neumann K, Leeb BF: A Meta-analysis of Controlled Clinical Studies With Diacerein in the Treatment of Osteoarthritis; Arch Int Med; 2006; 166: 1899-1906.
  53. Zhang W, M Doherty, B F Leeb, L Alekseeva, N K Arden, J W Bijlsma, F Dincer, K Dziedzic, H J Häuselmann, G Herrero-Beaumont, P Kaklamanis, S Lohmander, E Maheu, E Martín-Mola, K Pavelka, L Punzi, S Reiter, J Sautner, J Smolen, G Verbruggen, and I Zimmermann-Górska: EULAR evidence based recommendations for the management of hand osteoarthritis – report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT); Ann Rheum Dis. 2007 Mar;66(3):377-88. Epub 2006 Oct 17
  54. Zhang W, M Doherty, B F Leeb, L Alekseeva, N K Arden, J W Bijlsma, F Dincer, K Dziedzic, H J Häuselmann, Kaklamanlis P, Kloppenburg M, LS Lohmander, E Maheu, E Martín-Mola, K Pavelka, L Punzi, S Reiter, J Smolen, G Verbruggen, Watt I, and I Zimmermann-Górska. EULAR evidence based recommendations for the diagnosis of hand osteoarthritis – report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).Ann Rheum Dis. 2008 Feb 4; [Epub ahead of print]
  55. Dasgupta B, Salvarani C, Schirmer M, Crowson CS, Maradit-Kremers H, Hutchings A, Matteson EL; members of the American College of Rheumatology Work Group for Development of Classification Criteria for PMR. Developing classification criteria for polymyalgia rheumatica: comparison of views from an expert panel and wider survey.J Rheumatol. 2008 Feb;35(2):270-7. Epub 2007 Nov 15.
  56. Rintelen B, Haindl PM, Mai HTH, Sautner J, Maktari A, Leeb BF. A Tool for the assessment of hand involvement in rheumatic disorders in daily routine – the SF-SACRAH (Short Form Score for the Assessment and Quantification of Chronic Rheumatic Affections of the Hands). Osteoarthr&Cart, 2008, available online June 16th
  57. Rintelen B, Haindl PM, Maktari A, Nothnagl T, Hartl E, Leeb BF. SDAI/CDAI-Levels in Rheumatoid Arthritis Patients are Highly Determined by Patient’s Pain Perception and Gender Scand J Rheumatol, 2008; e-pub 2008, Aug 29
  58. Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J, Bombardier C, Carmona L, van der Heijde D, Bijlsma JW, Boumpas DT, Canhao H, Edwards CJ, Hamuryudan V, Kvien TK, Leeb BF, Martín-Mola EM, Mielants H, Müller-Ladner U, Murphy G, Ostergaard M, Pereira IA, Ramos-Remus C, Valentini G, Zochling J, Dougados M. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis. Published Online First: 25 November 2008. doi: https://doi.org/10.1136/ard.2008.094474
  59. Rintelen B, Haindl PM, Sautner J, Leeb BA, Deutsch C, Leeb BF. The RADAI-5 in daily use. Proposal for disease activity categories. J Rheumatol. 2009 May;36(5):918-24. Epub 2009 Mar 30.
  60. Sautner J, Andel I, Rintelen B, Leeb BF. A comparison of the M-SACRAH (Modified Score for the Assessment of Chronic Rheumatoid Affections of the Hands) and the AUSCAN (Australian/Canadian osteoarthritis hand index) in hand osteoarthritis patients. IJR, Volume 2009 (2009), Article ID 249096,
  61. Rintelen B, Sautner J, Haindl PM, Andel I, Maktari A, Leeb BF, Comparison of Three Rheumatoid Arthritis Disease Activity Scores in Clinical Routine. Scand J Rheumatol 2009, in press
  62. Zhang W, Doherty M, Bardin T, Barskova V, Guerne PA, Jansen TL, Leeb BF, Perez-Ruiz F, Pimentao J, Punzi L, Richette P, Sivera F, Uhlig T, Watt I, Pascual E. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis doi: https://doi.org/10.1136/ard.2010.139105.
  63. Zhang W, Doherty M, Pascual E, Barskova V, Guerne PA, Jansen TL, Leeb BF, Perez-Ruiz F, Pimentao J, Punzi L, Richette P, Sivera F, Uhlig T, Watt I, Bardin T. EULAR recommendations for calcium pyrophosphate deposition. Part II: Management. Ann Rheum Dis. 2011 Jan 20. [Epub ahead of print]
  64. Mc Williams DF, Leeb BF, Muthuri SG, Doherty M, Zhang W: Occupational risk factors for osteoarthritis. A meta-analysis. Osteoarthritis Cartilage. 2011 Jul;19(7):829-39. doi: https://doi.org/10.1016/j.joca.2011.02.016. Epub 2011 Mar 5. R
  65. Jimenez-Boj E, Stamm TA, Sadlonova M, Rovensky J, Raffayová H, Leeb B, Machold KP, Graninger WB, Smolen JS. Rituximab in psoriatic arthritis: an exploratory evaluation. Ann Rheum Dis. 2012 Nov;71(11):1868-71. doi: https://doi.org/10.1136/annrheumdis-2012-201897. Epub 2012 Jul 24.
  66. Rintelen B, Sautner J, Haindl PM, Mai H, Brezinschek HP, Leeb B: Remission in Rheumatoid Arthritis: A comparison of the 2 newly proposed ACR/EULAR remission criteria with the Rheumatoid Arthritis Disease Activity Index-5, a self-report Disease Activity Index. J Rheumatol. 2013 Apr;40(4):394-400. doi: 10.3899/jrheum.120952. Epub 2013 Feb 1.
  67. Sivera F, Andrés M, Carmona L, Kydd AS, Moi J, Seth R, Sriranganathan M, van Durme C, van Echteld I, Vinik O, Wechalekar MD, Aletaha D, Bombardier C, Buchbinder R, Edwards CJ, Landewé RB, Bijlsma JW, Branco JC, Burgos-Vargas R, Catrina AI, Elewaut D, Ferrari AJ, Kiely P, Leeb BF, Montecucco C, Müller-Ladner U, Ostergaard M, Zochling J, Falzon L, van der Heijde DM Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative Ann Rheum Dis. 2013 Jul 18. doi: 10.1136/annrheumdis 2013-203325. [Epub ahead of print]
  68. Puchner R, Brezinschek HP, Herold M, Nothnagl T, Studnicka-Benke A, Fritz J, Leeb BF. Quality of care of rural rheumatoid arthritis patients in Austria. Wien Klin Wochenschr. 2014 Jun;126(11-12):360-7. doi: https://doi.org/10.1007/s00508-014-0540-6
  69. Puchner R, Brezinschek HP, Fritz J, Herold M, Mustak M, Nothnagl T, Puchner SE, Studnicka-Benke A, Leeb BF. Is the state of health of rheumatoid arthritis patients receiving adequate treatment, predictable? – Results of a survey. BMC Musculoskelet Disord. 2015 May 6;16:109. doi: 10.1186/s12891-015-0567-5.
  70. Rintelen B, Zwerina J, MD, Herold M, Singer F, Hitzelhammer J, Halder W, Eichbauer-Sturm G, Puchner R, Stetter, MD M; Leeb BF: Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: Current practice of bDMARD therapy in Rheumatoid Arthritis in Austria. BMC Musculoskelet Disord. 2016
  71. Edwards MH, Parsons C, Bruyère O, Petit Dop F, Chapurlat R, Roemer FW, Guermazi A, Zaim S, Genant H, Reginster JY, Dennison EM, Cooper C; SEKOIA Study Group.High Kellgren-Lawrence Grade and Bone Marrow Lesions Predict Worsening Rates of Radiographic Joint Space Narrowing; The SEKOIA Study. J Rheumatol. 2016 Mar;43(3):657-65. doi: 10.3899/jrheum.150053. Epub 2016 Jan 15.
  72. Stummer U, Rintelen B, Leeb BF. The Short Form Score for the Assessment and Quantification of Chronic Rheumatic Affections of the Hands in Daily Clinical Routines-Its Sensitivity to Change and Preliminary Patient Relevant Variation Values: A Pilot Study. Front Med (Lausanne). 2017 Jan 27;4:6. doi: https://doi.org/10.3389/fmed.2017.00006
  73. Parsons CM, Judge A, Leyland K, Bruyère O, Petit Dop F, Chapurlat R, Reginster JY, Edwards MH, Dennison EM, Cooper C, Inskip H; SEKOIA Study Group. Novel Approach to Estimate Osteoarthritis Progression: Use of the Reliable Change Index in the Evaluation of Joint Space Loss. Arthritis Care Res (Hoboken). 2019 Feb;71(2):300-307. doi: 10.1002/acr.23596.
  74. Pinter G, Stromer W, Donnerer J, Geyrhofer S, Leeb B, Mitrovic N, Pils K, Likar R. Pain and pain management in old age: special features and recommendations Z Gerontol Geriatr. 2021 Oct;54(6):605-610. DOI: 10.1007/s00391-020-01765-8.
  75. Pinter G, Stromer W, Donnerer J, Geyrhofer S, Leeb B, Mitrovic N, Pils K, Likar R. Pain and pain management in old age: special features and recommendations. Z Gerontol Geriatr. 2021 Aug;54(5):507-512. doi: 10.1007/s00391-020-01765-8. Epub 2020 Jul 16.
  76. Lauper K, Ludici M, Mongin D, Bergstra SA, Choquette D, Codreanu C, Cordtz R, De Cock D, Dreyer L, Elkayam O, Hauge EM, Huschek D, Hyrich KL, Iannone F, Inanc N, Kearsley-Fleet L, Kristianslund EK, Kvien TK, Leeb BF, Lukina G, Nordström DC, Pavelka K, Pombo-Suarez M, Rotar Z, Santos MJ, Strangfeld A, Verschueren P, Courvoisier DS, Finckh A. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‚JAK-pot‘ collaboration. Ann Rheum Dis. 2022 Jun 15: annrheumdis-2022-222586. doi: https://doi.org/10.1136/annrheumdis-2022-222586. Online ahead of print.
  77. Pombo-Suarez M, Sanchez-Piedra C, Gómez-Reino J, Lauper K, Mongin D, Iannone F, Pavelka K, Nordström DC, Inanc N, Codreanu C, Hyrich KL, Choquette D, Strangfeld A, Leeb BF, Rotar Z, Rodrigues A, Kristianslund EK, Kvien TK, Elkayam O, Lukina G, Bergstra SA, Finckh A, Courvoisier DS. After JAK inhibitor failure: to cycle or to switch, that is the question – data from the JAK-pot collaboration of registries. Ann Rheum Dis. 2022 Sep 13: annrheumdis-2022-222835. doi: 10.1136/ard-2022-222835. Online ahead of print.

Radiological Vignette

  1. Leeb BF, Stenzel I, Czembirek H, Smolen JS: Diagnostic use of office based ultrasound. Baker’s cyst of the right knee joint. Arthr Rheum 1995; 38 (6): 859-861

Editorials, Reviews

  1. Leeb B: Kontrollmöglichkeiten bei low-dose Methotrexattherapie bei rheumatoider Arthritis und Arthritis psoriatica. Z Rheumatol 50/4; 280; 1991
  2. Leeb BF: Should folate supplementation be routinely recommended for older patients receiving methotrexate? Drugs-Aging 1994; 5(5): 319 – 322;
  3. Leeb BF, Machold KP, Smolen JS: Diagnose und Therapie der chronischen Polyarthritis. Radiologe 1996; 36: 657 – 662
  4. Leeb, B.F., Machold, K.P., Eberl, G., Zimmermann, C., Smolen, J.S. Drug therapy of chronic polyarthritis [Chronische Polyarthritis. Medikamentöse Therapie] Österreichische Ärztezeitung 1996 51 (15), pp. 24-26+29
  5. Leeb BF, Smolen JS: „Low-Dose“ Methotrexate therapy in rheumatoid arthritis – an update. Acta Med Austr 1996; 23 (4): 114 – 119
  6. Leeb BF, Machold KP: Sonography in rheumatology (The sound of arthritis); Rheumatology in Europe 1997; 26/3: 85
  7. Leeb BF, Pflugbeil S, Smolen JS: Sonography of the retrocalcaneal region: Achilles tendon and paratendine structures with respect to chronic inflammatory diseases. Rheumatology in Europe 1997; 26/3: 93 – 95
  8. Leeb BF, Weber K, Smolen JS: Rheumatoid Arthritis: Diagnosis and Screening. Disease Management & Health Outcomes 1998 Dec 4(6): 315 – 324
  9. Leeb BF, Sautner J: Anti-TNFα-Therapie als neue Option in der Behandlung der rheumatoiden Arthritis ? Wien Med Wschr. 1999; 149: 554 – 557
  10. Leeb BF: Rheumatologie – eine dynamische Disziplin. Wr. Med. Wschr. 2003, 153 (13/14): 290
  11. Leeb BF: Disease activity assessment in Polymyalgia Rheumatica (PMR) and Giant Cell Arteritis (GCA) Rheumatology 2005 44(suppl_3):iii5-iii6;
  12. Leeb BF Dokumentation der Krankheitsaktivität in der täglichen Routine. Akt. Rheumatol 2009, in press
  13. Leeb BF: Clinical Efficacy and Safety of Diacerein in Osteoarthritis – A Review. European Musculoskeletal Review, 2010;5(1)
  14. Leeb B, Thalhammer F: Tuberkulose und Biologika. Supplementum zur Österr Ärztezeitung 2011; März (www.oegit.eu)
  15. Leeb BF, Sautner J: Gicht – Harnsäure: Wann senken und wie stark? UIM 09/2012
  16. Leeb BF: BioReg: Stand der Dinge rheuma plus March 2013, Volume 12, Issue 1, p 14
  17. Leeb BF. RA-Patienten im Biological-Register. rheuma plus Juli 2013, Volume 12, Issue 2, pp 22-24
  18. Leeb BF, Haindl PM, Brezinschek HP, Nothnagl T, Rintelen B: RADAI-5 to monitor Rheumatoid Arthritis. Clin Exp Rheumatol. 2014 Sep-Oct;32 (5 Suppl 85):S-55-8. Epub 2014 Oct 30.
  19. Leeb BF, Mai HTH: Smoking. Does It Affect Rheumatoid Arthritis Activity? Does It Matter? J Rheumatol July 2015 42(7):1072-1074; doi: https://doi.org/10.3899/jrheum.150491
  20. Leeb BF: Should physicians‘ consider patient perception for modulating treatment? Rheumatology (Oxford). 2016 Nov;55(11):1919-1920. Epub 2016 Jun 21.
  21. Leeb BF, Brezinschek HP, Rintelen B: RADAI-5 and electronic monitoring tools. Clin Exp Rheumatol. 2016 Sep-Oct;34 (5 Suppl 85): 05-10. Epub 2014 Oct21.
  22. Leeb BF. Weg vom Mittelwert. Rheuma plus; Oct 2016
  23. Leeb BF. Der Patient ist das Target. Rheuma plus; Aug 2017
  24. Leeb BF. Wie geht es weiter? Rheuma plus; Nov 2017
  25. Leeb BF. Patient Reported Outcomes Compared to Composite Indexes in Routine Disease Activity Assessment of Rheumatoid Arthritis. Am J Arthritis Res. 2017; 1(1): 1005
  26. Leeb BF. Wird 2018 ein Jahr der Veränderungen?, Rheuma plus; Feb 2018
  27. Leeb BF. Rheumatologie ist mehr als die Behandlung von Autoimmunerkrankungen. Rheuma plus; Mar 2018
  28. Leeb BF, Fabsits T. Daten aus dem BioReg Biologika-Therapie bei rheumatoider Arthritis in Österreich. Rheuma plus; Mar 2018
  29. Leeb BF. Was wollen die Patienten eigentlich vom Rheumatologen? Rheuma plus; Jun 2018
  30. Leeb BF Persönliche Expertise. Noch gefragt? Rheuma plus August 2018, Volume 17, Issue 4, pp 107–107
  31. Leeb BF. Rheuma kommt selten allein. Rheuma plus October 2018, Volume 17, Issue 5, pp 145–145
  32. Leeb BF. Treat to Target – Alles Gut? rheuma plus November 2018, Volume 17, Issue 6, pp 177–177
  33. Leeb BF. Allgemeinmediziner und Rheumatologe, rheuma plus February 2019, Volume 18, issue 1, pp 1–1
  34. Leeb BF. Grün – die Farbe der Hoffnung. rheuma plus April 2019, Volume 18, Issue 2, pp 37–37
  35. Leeb BF. Adhärenz – für Patienten und Ärzte Dasselbe? rheuma plus June 2019, Volume 18, Issue 3, pp 79–79
  36. Leeb BF. Wer teilt mit wem welche Entscheidung? rheuma plus August 2019, Volume 18, issue 4, p0 113,
  37. Leeb BF (2019) A Plea for Patient Centered Treatment-Isn’t Individualized Therapy the Highest Precept? Rheumatology (Sunnyvale). 9:251. doi: https://doi.org/10.35248/2161-1149.19.9.251
  38. Leeb BF: Vom Privileg Rheumatologe zu sein. rheuma plus (2019) 18: 151. https://doi.org/10.1007/s12688-019-00290-w
  39. Leeb BF. Klinische Studien – Real World Data. Ein Spannungsfeld? Rheuma plus (2019) Volume 18, Issue 6, pp 189–190
  40. Leeb BF. | Patient-reported Outcomes (PROs). UIM 09/2019
  41. Leeb BF. Ärzte und Piloten, kein Vergleich. rheuma plus (2020) 19: 1. https://doi.org/10.1007/s12688-020-00319-5
  42. Leeb BF Es gibt auch noch etwas Anderes. rheuma plus 2020 · 19:39- https://doi.org/10.1007/s12688-020-00330-w
  43. Leeb BF. Sag mir, wo ist die Evidenz geblieben? rheuma plus 2020 · 19:82–83 https://doi.org/10.1007/s12688-020-00342-6
  44. Leeb BF Second Wave, Third Wave, Does It Matter? Rheuma Plus. 2020;19(6):200-201. doi: https://doi.org/10.1007/s12688-020-00390-y. Epub 2020 Nov 6. PMID: 33173545
  45. Leeb BF Biosimilars in der Rheumatologie – Status quo in BioReg. UIM 04/2020
  46. Leeb BF Education in Times of the Pandemic, Change of Paradigms? Rheuma Plus. 2020;19(5):160-161. doi: https://doi.org/10.1007/s12688-020-00381-z. Epub 2020 Sep 23. PMID: 32983276
  47. Leeb BF. Das Fibromyalgiesyndrom aus rheumatologischer Sicht UIM 06/2020
  48. Leeb BF The somewhat different summer 2020. Rheuma Plus. 2020;19(4):120-121. doi: https://doi.org/10.1007/s12688-020-00357-z. Epub 2020 Aug 4. PMID: 32834862
  49. Leeb BF, Schöfl R PPI (Protonenpumpeninhibitoren) zur Prävention gastrointestinaler Ereignisse bei NSAR-Gabe. Schmerz Nachr 4/2020; 49-53
  50. Leeb BF Time is Rushing by-Rheuma Plus is Rushing Along. Rheuma Plus. 2021;20(4):135-137. doi: https://doi.org/10.1007/s12688-021-00457-4. Epub 2021 Aug 9. PMID: 34394763
  51. Leeb BF There is no Getting Around Corona. Rheuma Plus. 2021;20(1):2-3. doi: https://doi.org/10.1007/s12688-021-00417-y. Epub 2021 Feb 22. PMID: 33643477
  52. Leeb BF What could a new disease activity score for polymyalgia rheumatica do better? Nat Rev Rheumatol. 2021 Mar;17(3):185. doi: https://doi.org/10.1038/s41584-020-00550-6. PMID: 33257871
  53. Leeb BF Klinische Differenzialdiagnostik des Gelenkschmerzes Schmerz Nachr 2022 · 22:185–192 https://doi.org/10.1007/s44180-022-00050-x
  54. Leeb BF. Diagnose Ankylosierende Spondylitis. Behandlung im Netzwerk. AEK 19/2022; 6-7
  55. Sautner J und Leeb BF: Biologika in der Behandlung der Rheumatoiden Arthritis und anderer entzündlicher Arthropathien, Wr. Med. Wschr. 2003, 153 (13/14): 304 – 308
  56. Nothnagl Th, Leeb BF: Polymyalgia rheumatica – ein klinischer Überblick. J Mineral Stoffwechs 2004; 11(1): 37 – 39
  57. Rintelen B, Leeb BF: Entzündlich rheumatischer Formenkreis – eine Übersicht. J Mineral Stoffwechs 2004; 11(1): 31 – 36
  58. Sautner J, Leeb BF: Moderne antirheumatische Pharmakotherapie: Niedermolekulare Substanzen vs. Biologicals. [Up-to-date antirheumatic therapy: Methotrexate vs. biologicals.] Internist (Berl). 2005 Dec;46(12):1399-404.
  59. Nothnagl Th, Leeb BF: Diagnosis, differential diagnosis and treatment of Polymyalgia Rheumatica. Drugs & Aging, 2006;23(5):391-402.
  60. Rintelen B, Leeb BF: Medikamentöse Therapie entzündlich rheumatischer Erkrankungen in der Schwangerschaft unter besonderer Berücksichtigung der rheumatoiden Arthritis. Speculum, 2006; 24(4) 7 – 11
  61. Rintelen B, Sautner J, Herold M, Leeb BF: Empfehlungen zur NSAR Therapie –Erste Erfahrungen mit einem Delphi-Prozess in Österreich. Akt Rheumatol 2007; 32: 255-261
  62. Grusch B, Rintelen B, Leeb BF. Evidenzbasierte Empfehlungen der „European League Against Rheumatism“ zur Diagnostik und Therapie der Gicht. Z Rheumatol. 2007 Nov;66(7):568-572.
  63. Brezinschek HP, Hofstaetter T, Leeb BF, Haindl P, Graninger WB. Immunization of patients with rheumatoid arthritis on anti-TNFα-therapy and methotrexate. Curr Op Rheumatol. 2008, 2008 May;20(3):295-299.
  64. Olivé, A., Monteagudo, I., Wolf, A., Leeb, B., Graninger, W., Poriau, S., Steinfeld S, Cikes N, Klerides M, Pavelka, K., Faarvang, K., Nielsen, E., Leirisalo-Repo, M., Kauppi, M., Sanchez, J.-P., Duquesnoy, B., Bandilla, K., Wollenhaupt, J., Burmester, G., Sakkas, L., Sfikakis, P., Hodinka, L., Gomor, B., Guobjörnsson, B., Ragnarsson, A.T., Duffy, T., O’Connell, P., Scarpa, R., Valesini, G., Camilleri, F., Gilboe, I.-M., Da Silva, J., Da Silva, J.C., Bolosiu, H., Tomsic, M., Proprotnik, S., Olivé, À., Petersson, I., Wollheim, F., Aeschlimann, A., Gerber, H., Kruijsen, M., Bijlsma, H., Yaziki, H., Fresko, I., Bax, D., Doherty, M., Kvien, T. The health system for patients with rheumatic disease: A rheumatology service [Sistema sanitario para los pacientes con enfermedades reumáticas: Un servicio de reumatología] Seminarios de la Fundacion Espanola de Reumatologia Volume 8, Issue 3, 1 July 2007, Pages 130-144
  65. Haindl PM, Reiter S, Leeb BF. Evidenzbasierte Empfehlungen der European League against Rheumatism zur Diagnose und Therapie der Hand-Arthrose. Akt. Rheumatol 2008; 33: 342-350
  66. Machold KP, Brezinschek HP, Leeb BF, Pflugbeil S, Rainer F, Singer F, Skoumal M, Stamm TA, Herold M: Österreichische Expertenmeinung zum Standard der Verlaufsbeurteilung von Patienten mit chronischer Polyarthritis (rheumatoider Arthritis). Wr Klin Wschr (2008): 120/7-8: 234-241
  67. Schwarzenfeld C, Haindl PM, Rintelen B, Leeb BF. Polyunsaturated Fatty Acids and Rheumatoid Arthritis. Curr Top Nutr Res, 2009 in press
  68. Rintelen B, Leeb BF Krankheitsaktivitätsindizes bei rheumatoider Arthritis in der täglichen Praxis. J Mineral Stoffwechs 2009
  69. Steindl M, Nothnagl T, Andel I, Leeb BF Diagnose und Monitoring bei Polymyalgia Rheumatica; Akt Rheumatol 2009; 34: 171-174; DOI: https://doi.org/10.1055/s-0029-1225346
  70. Rintelen B, Leeb BF Rheumatoide Arthritis – Warum können wir auf joint counts in der Routine verzichten? Disease Activity Measurement in Rheumatoid Arthritis – Why is a Joint Count abdicable? Akt Rheumatol 2009; 34: 167-170, DOI: https://doi.org/10.1055/s-0029-1225345
  71. Rintelen B, Brezinschek HP, Sautner J, Herold M, Leeb BF. Update von 10 Empfehlungen zur Therapie mit NSAR; Akt. Rheumatol 2009, online first 10. 3. 2010
  72. Olivé, A., Monteagudo, I., Wolf, A., Leeb, B., Graninger, W., Poriau, S., Steinfeld S, Cikes N, Klerides M, Pavelka, K., Faarvang, K., Nielsen, E., Leirisalo-Repo, M., Kauppi, M., Sanchez, J.-P., Duquesnoy, B., Bandilla, K., Wollenhaupt, J., Burmester, G., Sakkas, L., Sfikakis, P., Hodinka, L., Gomor, B., Guobjörnsson, B., Ragnarsson, A.T., Duffy, T., O’Connell, P., Scarpa, R., Valesini, G., Camilleri, F., Gilboe, I.-M., Da Silva, J., Da Silva, J.C., Bolosiu, H., Tomsic, M., Proprotnik, S., Olivé, À., Petersson, I., Wollheim, F., Aeschlimann, A., Gerber, H., Kruijsen, M., Bijlsma, H., Yaziki, H., Fresko, I., Bax, D., Doherty, M., Kvien, T. The health system for patients with rheumatic disease: A rheumatology service [Sistema sanitario para los pacientes con enfermedades reumáticas: Un servicio de reumatología] Seminarios de la Fundacion Espanola de Reumatologia Volume 8, Issue 3, 1 July 2007, Pages 130-144
  73. Hazlewood G, Aletaha D, Carmona L, Landewé RB, van der Heijde DM, Bijlsma JW, Bykerk VP, Canhão H, Catrina AI, Durez P, Edwards CJ, Leeb BF, Mjaavatten MD, Martinez-Osuna P, Montecucco C, Ostergaard M, Serra-Bonett N, Xavier RM, Zochling J, Machado P, Thevissen K, Vercoutere W, Bombardier C Algorithm for identification of undifferentiated peripheral inflammatory arthritis: a multinational collaboration through the 3e initiative. J Rheumatol Suppl. 2011 Mar;87:54-8. doi: https://doi.org/10.3899/jrheum.101076. Review.
  74. Machado P, Castrejon I, Katchamart W, Koevoets R, Kuriya B, Schoels M, Silva-Fernández L, Thevissen K, Vercoutere W, Villeneuve E, Aletaha D, Carmona L, Landewé R, van der Heijde D, Bijlsma JW, Bykerk V, Canhão H, Catrina AI, Durez P, Edwards CJ, Mjaavatten MD, Leeb BF, Losada B, Martín-Mola EM, Martinez-Osuna P, Montecucco C, Müller-Ladner U, Ostergaard M, Sheane B, Xavier RM, Zochling J, Bombardier C. Multinational evidence-based recommendations on how to investigate and follow-up undifferentiated peripheral inflammatory arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis. 2010 Aug 19. [Epub ahead of print]
  75. Haindl PM, Rintelen B, Brezinschek HP, Herold M, Eberl G, Wolf J Machold KP, Nothnagl T, Leeb BF. Österreichische Empfehlungen zum Gebrauch von Methotrexat in der Rheumatologie – Expertenkonsensus basierend auf einer systematischen Literatursuche. Akt. Rheumatol 2010, online first 5. 3. 2010
  76. Jansen TL, Richette P, Perez-Ruiz F, Tausche AK, Guerne P-A, Punzi L, Leeb B, Barskova V, Uhlig T, Pimentão J, Zimmermann-Górska I, Pascual E, Bardin Th, Doherty M. International position paper on Febuxostat; Clin Rheum 2010, in press
  77. Hazlewood G, Aletaha D, Carmona L, Landewé RB, van der Heijde DM, Bijlsma JW, Bykerk VP, Canhão H, Catrina AI, Durez P, Edwards CJ, Leeb BF, Mjaavatten MD, Martinez-Osuna P, Montecucco C, Ostergaard M, Serra-Bonett N, Xavier RM, Zochling J, Machado P, Thevissen K, Vercoutere W, Bombardier C. Algorithm for identification of undifferentiated peripheral inflammatory arthritis: a multinational collaboration through the 3e initiative. J Rheumatol Suppl. 2011 Mar;87:54-8.
  78. Whittle SL, Colebatch AN, Buchbinder R, Edwards CJ, Adams K, Englbrecht M, Hazlewood G, Marks JL, Radner H, Ramiro S, Richards BL, Tarner IH, Aletaha D, Bombardier C, Landewé RB, Müller-Ladner U, Bijlsma JW, Branco JC, Bykerk VP, da Rocha Castelar Pinheiro G, Catrina AI, Hannonen P, Kiely P, Leeb B, Lie E, Martinez-Osuna P, Montecucco C, Ostergaard M, Westhovens R, Zochling J, van der Heijde D. Multinational evidence-based recommendations for pain management by pharmacotherapy in Inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative; Rheumatology 2012 advance access 10.1093/rheumatology/kes032
  79. Thalhammer F, Leeb B: Biologika und nicht tuberkulöse Infektionen. Supplementum zur Österr Ärztezeitung 2012; Juli (www.oegit.eu)
  80. Sautner J, Gruber J, Herold M, Zwerina J, Leeb BF. Austrian 3e-recommendations for diagnosis and management of gout 2013. Österreichische 3e-Empfehlungen zu Diagnose und Management von Gicht2013. Wien Klin Wochenschr. 2014 Feb;126(3-4):79-89
  81. Pavelka K, Bruyère O, Cooper C, Kanis JA, Leeb BF, Maheu E, Martel-Pelletier J, Monfort J, Pelletier JP, Rizzoli R, Reginster JY. Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. Drugs Aging. 2016 Feb;33(2):75-85. doi: 10.1007/s40266-016-0347-4
  82. Edwards MH, Parsons C, Bruyère O, Petit Dop F, Chapurlat R, Roemer FW, Guermazi A, Zaim S, Genant H, Reginster JY, Dennison EM, Cooper C; SEKOIA Study Group. High Kellgren-Lawrence Grade and Bone Marrow Lesions Predict Worsening Rates of Radiographic Joint Space Narrowing; The SEKOIA Study. J Rheumatol. 2016 Mar;43(3):657-65. doi: 10.3899/jrheum.150053. Epub 2016 Jan 15.
  83. Lechner G, Leeb BF. Polymyalgia rheumatica. Ein Überblick. Internistische Praxis 57, 1–9 (2016)
  84. van Riel P, Alten R, Combe B, Abdulganieva D, Bousquet P, Courtenay M, Curiale C, Gómez-Centeno A, Haugeberg G, Leeb B, Puolakka K, Ravelli A, Rintelen B, Sarzi-Puttini P. Improving inflammatory arthritis management through tighter monitoring of patients and the use of innovative electronic tools. RMD Open. 2016 Nov 24;2(2):e000302.
  85. Reginster JY, Arden NK, Haugen IK, Rannou F, Cavalier E, Bruyère O, Branco JC, Chapurlat R, Collaud S, Nasser B, Al-Daghri M, Dennison EM, Herrero-Beaumont G, Laslop A, Leeb BF, Maggi S, Mkinsi O, Povzun AS, Prieto-Alhambra D, Thomas T, Uebelhart D, Veronese N, Cooper C. Guidelines for the conduct of pharmacological clinical trials in hand osteoarthritis: Consensus of a Working Group of the European Society on Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). December 2017, Seminars in Arthritis and Rheumatism. DOI 10.1016/j.semarthrit.2017.12.003
  86. Bröll H, Lunzer R, Nothnagl T, Bauer B, Leeb BF. The Efficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis: An Austrian Non-Interventional Study. Am J Arthritis Res. 2018; 2(1): 1012

    Case Reports, Letters:
  87. Leeb BF: Glucosamine and Chondroitin sulfate for the treatment of osteoarthritis: Arthritis Rheum (Arthr Care Res), 45 (6) 2001; 537
  88. Leeb BF: Management of knee osteoarthritis. Ann Rheum Dis. 2001 Oct;60(10):984er. 2008;88: 1716-1727. PTjournal 2008 88: p. 407-408
  89. Leeb BF: Hotel Based Rheumatology, and More. J Rheumatol 2008, in press
  90. Leeb BF: War Vietnam schuld? rheuma plus, March 2013, Volume 12, Issue 1, p 18
  91. Leeb B. Comments on Alegría and Irarrázaval (2017): Is diacerein an alternative for the treatment of osteoarthritis? Medwave 2018 Mar-Abr;18(2):e7193 doi: https://doi.org/10.5867/medwave.2018.02.7193
  92. Leeb BF. Ende gut, alles gut – aber bitte nicht Schwamm drüber. Polymyalgia rheumatica oder Riesenzellarteriitis? rheuma plus https://doi.org/10.1007/s12688-020-00352-4
  93. Rintelen B, Leeb B: Die Anamnese – Die Kriterien in der Rheumatologie. J Mineral Stoffwechs 2003, 10 (3): 32
  94. Rintelen B, Leeb B: Kristallarthropathie. J Mineral Stoffwechs 2003, 10 (4): 25 – 26
  95. Fassl C, Sautner J, Rintelen B, Leeb BF. Intravenous Application of Omega-3 Fatty Acids in a Patient with Active Spondylarthropathy – a Case Report. Clin Rheumatol. 2006; 25; 577 – 578; Epub ahead of print: Oct 12th 2005
  96. Gossec L, Bijlsma JW, Bombardier C, Canhão H, Devlin J, Edwards CJ, Hamuryudan V, Kvien TK, Leeb BF, Martín-Mola EM, Mielants H, Müller-Ladner U, Ostergaard M, Pereira IA, Ramos-Remus C, Zochling J, Dougados M. Dissemination and evaluation of the 3E initiative recommendations for use of methotrexate in rheumatic disorders: results of a study among 2233 rheumatologists. Ann Rheum Dis. 2010 May 14. [Epub ahead of print]
  97. Sautner J, Rintelen B, Leeb BF: Efficacy of Rituximab treating severe subcutaneous nodulosis in rheumatoid arthritis, Rheumatology (Oxford). 2013 Aug;52(8):1535-7. doi: https://doi.org/10.1093/rheumatology/kes406. Epub 2013
  98. Hanserl A, Sautner J, Leeb BF. Cryptococcal Meningi¬tis as a Fatal Complication of Sarcoidosis. Am J Clin Case Rep. 2020;1(1):1014.
  99. Ferincz V, Schöls K, Leeb BF, Maieron A. Fallbericht und Review (Case Report and Review): Symmetrische Gelenkschwellung bedeutet nicht automatisch Arthritis (Bilateral Joint Swelling Does Not Automatically Mean Arthritis) September 2021 rheuma plus DOI: https://doi.org/10.1007/s12688-021-00442-x

Buchbeiträge

  1. Leeb B, Thumb N: Immunsuppressiva. In: Bröll H, Czurda R, Siegmeth W, Smolen J, Thumb N (eds.): Praktische Rheumatologie; Blackwell Wissenschaftsverlag Berlin – Wien 1996; 461 – 464
  2. Leeb B: Medikamenteninduzierte rheumatische Syndrome. In: Bröll H, Czurda R, Siegmeth W, Smolen J, Thumb N (eds.): Praktische Rheumatologie; Blackwell Wissenschaftsverlag Berlin – Wien 1996; 409 – 412
  3. Leeb BF, Sautner J: Chondrocalcinose. In: Thumb N Bröll H, Czurda R, Siegmeth W, Smolen J,(eds.): Praktische Rheumatologie, Springer-Verlag 4. Auflage; 2001, 259
  4. Leeb BF, Sautner J: Hydroxyapatitkrankheit: In: Thumb N Bröll H, Czurda R, Siegmeth W, Smolen J, (eds ) Praktische Rheumatologie, Springer-Verlag 4. Auflage 2001, 262
  5. Leeb BF: Medikamenteninduzierte rheumatische Syndrome: In: Thumb N Bröll H, Czurda R, Siegmeth W, Smolen J, (eds ) Praktische Rheumatologie, Springer-Verlag 4. Auflage 2001; 407
  6. Leeb BF: Andere Immunsuppressiva: In: Thumb N Bröll H, Czurda R, Siegmeth W, Smolen J, (eds ) Praktische Rheumatologie, Springer-Verlag 4. Auflage 2001; 459
  7. Leeb BF, Thumb N: Methotrexat: In: Thumb N Bröll H, Czurda R, Siegmeth W, Smolen J (eds.) Praktische Rheumatologie, Springer-Verlag 4. Auflage 2001; 453
  8. Leeb BF: SYSADOA/DMOAD: Neue therapeutische Konzepte bei Arthrose. In Thumb N, Bröll H, Czurda R, Siegmeth W, Smolen J, (eds.) Praktische Rheumatologie, Springer-Verlag 4. Auflage 2001; 469
  9. Leeb BF: Medikamentöses Langzeittherapiekonzept bei Chronischer Polyarthritis. In Ulreich A, Wagner E (eds.): Rehabilitation bei Chronischer Polyarthritis, Manz Crossmedia, 2001; 9 – 16
  10. Leeb BF, Smolen JS: Arthritis psoriatica. In Ganten D, Ruckpaul K (eds.): Molekularmedizinische Grundlagen von rheumatischen Erkrankungen. p. 377 – 386 Springer-Verlag 2003
  11. Leeb BF, Nothnagl T, Steindl M, Rintelen B. Diagnostic Criteria, Treatment, and Monitoring of Polymyalgia Rheumatica/Giant Cell Arteritis. In Polymyalgia Rheumatica and Giant Cell Arteritis Rovensky, J.;
  12. Leeb, B.F.; Bird, H.; Štvrtinová, V.; Imrich, R. (Eds.) 1st Edition, 2010, Springer-Verlag ISBN: 978-3-211-99358-3
  13. Leeb BF: SYSADOA/DMOAD: in Dunky A., Graninger W, Herold M, Smolen J, Wanivenhaus A (eds.) Praktische Rheumatologie, Springer-Verlag 5. Auflage 2012
  14. Leeb BF: Biologicals: A Perspective for the Treatment of PMR/GCA; in Polymyalgia Rheumatica and Giant Cell Arteritis (Rovenky J, Leeb BF et al. edts.); July 2017; DOI https://doi.org/10.1007/978-3-319-52222-7_12
  15. Leeb BF: Monitoring Tools for Polymyalgia Rheumatica/Giant Cell Arteritis; in Polymyalgia Rheumatica and Giant Cell Arteritis (Rovenky J, Leeb BF et al. edts.); July 2017; DOI https://doi.org/10.1007/978-3-319-52222-7_13
  16. Rainer F, Pongratz R, Bröll J, Czurda R, Dunky A, Graninger W, Leeb B et. al. Magenschutz bei Therapie mit nichtsteroidalen Antirheumatika. In Thumb N, Bröll H, Czurda R, Siegmeth W, Smolen J, (eds.) Praktische Rheumatologie, Springer-Verlag 4. Auflage 2001; 593
  17. Arbeitsgruppe der ÖGR – Graninger W, Leeb B, Thumb N, Wagner E: Richtlinien zur Behandlung mit Basistherapeutika (DMARD). In Thumb N, Bröll H, Czurda R, Siegmeth W, Smolen J, (eds ) Praktische Rheumatologie, Springer-Verlag 4. Auflage 2001; 597
  18. Rainer F, Bröll H, Czurda R, Dunky A, Graninger W, Kolarz G, Leeb B et al.: Leitlinie für die Radiosynoviorthese. In Thumb N, Bröll H, Czurda R, Siegmeth W, Smolen J, (eds.) Praktische Rheumatologie, Springer-Verlag 4. Auflage 2001; 617
  19. Singer F, Leeb B, Machold K, Ulreich A, Wagner E.: Leitlinien zur Qualitätssicherung in der Rheumatologie. www.rheuma2000.at; 2002
  20. Graninger W, Leeb B, Wagner E: Konsensusstatement der ÖGR für den Arzt zur Basistherapie der chronischen Polyarthritis und anderen entzündlichen Gelenkerkrankungen. 12/2006; www. Rheuma2000.at
  21. Rovensky J, Leeb BF, Štvrtinová V, Imrich R, Duda J. Polymyalgia Rheumatica and Giant Cell Arteritis – an overview with a focus on important factors contributing to the severity of the disease. In Polymyalgia rheumatica and Giant Cell Arteritis (J Rovensky ed.) 2007; 7 – 32; Slovak Academic Press
  22. Rovensky J, Leeb BF, Štvrtinová V, Imrich R, Duda J. Polymyalgia Rheumatica and Giant Cell Arteritis – an overview with a focus on important factors contributing to the severity of the disease. In Polymyalgia Rheumatica and Giant Cell Arteritis Rovensky, J.; Leeb, B.F.; Bird, H.; Štvrtinová, V.; Imrich, R. (Eds.) 1st Edition, 2010, Springer-Verlag ISBN: 978-3-211-99358-3
  23. Steindl M, Nothnagl Th, Leeb BF: Polymyalgia rheumatica (PMR): in In Dunky A., Graninger W, Herold M, Smolen J, Wanivenhaus A (eds.) Praktische Rheumatologie, Springer-Verlag 5. Auflage 2012
  24. Sautner J, Leeb BF: Gicht; in Dunky A., Graninger W, Herold M, Smolen J, Wanivenhaus A (eds.) Praktische Rheumatologie, Springer-Verlag 5. Auflage 2012
  25. Erlacher L., Leeb BF. Arthrosen grosser Gelenke: in Dunky A., Graninger W, Herold M, Smolen J, Wanivenhaus A (eds.) Praktische Rheumatologie, Springer-Verlag 5. Auflage 2012
  26. Aletaha D, Leeb BF: Methotrexat: in Dunky A., Graninger W, Herold M, Smolen J, Wanivenhaus A (eds.) Praktische Rheumatologie, Springer-Verlag 5. Auflage 2012
  27. Doherty M, Leeb BF, Haindl PM Osteoarthritis treatment (31) EULAR Textbook on Rheumatic Diseases, 1st edition, 2012
  28. Leeb BF, Dziedzic KS, Paskins Z. Osteoarthritis treatment. EULAR Textbook on Rheumatic Diseases, 2nd edition, 2015
  29. Rovensky J, Leeb BF, Strtvinova V, Imrich R, Duda J. Polymyalgia Rheumatica and Giant Cell Arteritis: An Overview with a Focus on Important Factors Contributing to the Severity of the Disease. In: Polymyalgia Rheumatica and Giant Cell Arteritis (Rovensky J, Leeb BF et al. edts.); July 2017; DOI https://doi.org/10.1007/978-3-319-52222-7_1
  30. Leeb BF. Biologicals: A Perspective for the Treatment of PMR/GCA. In: Polymyalgia Rheumatica and Giant Cell Arteritis (Rovensky J, Leeb BF et al. edts.); July 2017; DOI https://doi.org/10.1007/978-3-319-52222-7_12
  31. Leeb BF. Monitoring Tools for Polymyalgia Rheumatica/Giant Cell Arteritis. In: Polymyalgia Rheumatica and Giant Cell Arteritis (Rovensky J, Leeb BF et al. edts.); July 2017; DOI https://doi.org/10.1007/978-3-319-52222-7_13